HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Real life study of three years omalizumab in patients with difficult-to-control asthma.

AbstractBACKGROUND:
Even though there are multiple options for the treatment of asthma, there still exists a fair group of patients with difficult-to-control asthma. We describe for the first time the real-world effects of three-year omalizumab treatment on patients with difficult-to-control asthma, seen in a social security hospital in a Latin American country.
METHODS:
Difficult-to-control asthmatic patients from the out-patient clinic of a regional hospital were recruited to receive a three-year omalizumab course. Efficacy parameters were asthma control test (ACT) score; FEV1; daily beclomethasone maintenance dose; and unplanned visits for asthma exacerbations (emergency room (ER), hospitalisations, intensive care).
RESULTS:
52 patients were recruited, 47 completed the three-year treatment (42 female, 15-67 years, mean age 43.5). Comparing efficacy parameters of the year before omalizumab with the 3rd year of omalizumab: mean ACT improved from 12.4 to 20.5, mean FEV1 from 66.3% (standard deviation (SD) 19.1%) to 88.4% (SD 16.2%) of predicted, while mean beclomethasone dose reduced from 1750 to 766 mcg/day and there was a significant reduction in patients experiencing ER visits (from 95% to 19%, p<0.0001), hospitalisation (38% to 2%, p<0.0001) and intensive care (4% to 0, NS). Five patients discontinued omalizumab, two because of an adverse event (anaphylaxis, severe headache, both resolved without sequelae).
CONCLUSION:
Omalizumab improved most clinical parameters of Mexican patients with difficult-to-control asthma. Especially the rates of ER visits and hospitalisation were significantly reduced, thus reducing costs. Omalizumab was generally well tolerated.
AuthorsJ Jesús López Tiro, E Angélica Contreras Contreras, M Elena Ramírez del Pozo, J Gómez Vera, D Larenas Linnemann
JournalAllergologia et immunopathologia (Allergol Immunopathol (Madr)) 2015 Mar-Apr Vol. 43 Issue 2 Pg. 120-6 ISSN: 1578-1267 [Electronic] Singapore
PMID24780091 (Publication Type: Journal Article, Observational Study)
CopyrightCopyright © 2013 SEICAP. Published by Elsevier Espana. All rights reserved.
Chemical References
  • Anti-Asthmatic Agents
  • Omalizumab
  • Immunoglobulin E
  • Beclomethasone
Topics
  • Adolescent
  • Adult
  • Aged
  • Anti-Asthmatic Agents (therapeutic use)
  • Asthma (drug therapy)
  • Beclomethasone (therapeutic use)
  • Disease Progression
  • Emergency Medical Services
  • Female
  • Humans
  • Immunoglobulin E (immunology)
  • Male
  • Mexico
  • Middle Aged
  • Omalizumab (therapeutic use)
  • Respiratory Function Tests
  • Time Factors
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: